Development Training

Haibei Hu

Email: *********@********.***

Address: **** **** *******

City: Hoover

State: AL

Zip: 35216

Country: USA

Phone: 617-***-****

Skill Level: Experienced

Salary Range: $88,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

HAIBEI HU, Ph.D.

2823 Rime Village,

Hoover, AL 35216

Phone: 617-***-**** (mobile)

Email: *********@********.***

CAREER OBJECTIVE An experienced Molecular Pharmacologist seeking Scientist, Sr. Scientist, Principle Scientist position in pre-clinical R&D in pharmaceuticals, biotechs, diagonistics and CROs.

HIGHLIGHTS OF QUALIFICATION

* Molecular Pharmacology-trained research scientist with 5 years post-Ph.D. experience on bioanalytical assay development, investigational in vitro research, pre-clinical therapeutics development, biotech product development.

* Independently design, execute, perform and interpret complex bioanalytical assays for biological characterization and testing of biopharmaceutical products.

* Broad expertise in cell and molecular biology, protein chemistry and analytical technologies.

* Proven capability of documenting technology and projects in reports, SOPs, manuscripts, publications and business presentations.

* Excellent written and oral communication skills. Adapted working with multi-disciplinary and cross-functional teams. Efficient and innovative self-starter.

RESEARCH EXPERIENCE

09/2009-12/2012 Research Scientist

Biochemical Technologies, Corning Incorporated, Corning, NY, USA

* Reported to Corporate Research Fellow. Developed biochemical and cell-based assays using Corning Label-free Epic(R) technology for GPCRs, ion channels, RTKs using NCI cell lines or primary cell lines, focused on target/biomarker identification, G protein signaling pathway deconvolution and in vitro pharmacology profiling. Achieved 2 patent applications and 6 publications within 3 years.

* Co-invented Label-free Cellular Profiling Service (Corning(R) Epic(R) Pharmacology), commercialized contract research program provided by Corning Life Science for drug discovery pre-clinical R&D, brought in about $1-2M revenue since its launch in Q3, 2011.

* Implemented methodology for studying stem cell differentiation and reprogramming using Label-free. Established SOPs for viral method infection for transforming fibroblasts to iPSc, iPS differentiation and neurostem cell differentiation.

08/2007-07/2009 Post-doctoral Research Fellow

Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

* Investigated and identified several key molecular neuropathology and molecular events that lead to development of Huntington`s Disease and other triplet neurological disorders spinocerebellar ataxia (SCA).

* Accomplished 150,000 compounds high-throughput screening project in Harvard NeuroDiscovery center for identifying hit-to-lead drug candidates for therapeutically targeting Huntington`s Disease. 20 hits were identified and validated in secondary screen.

* Attained knowledge about neurodegenerative disorders and their therapeutic interventions (Parkinson`s Disease and Alzheimer`s Disease).

03/2002-12/2004 Molecular Biology Research Associate

NovaNeuron Inc, Halifax, Canada

* Responsible for designing and performing biochemical binding assays for identifying PDE10A inhibitors as potential therapeutic compounds in animal and cell culture models of Huntington`s Disease and schizophrenia.

PROFESSIONAL SKILLSETS

Bioanalytical

* Hand-on with high-throughput screening with cell-based label-free assays, reporter assays, FRET, shRNA target screening and imaging high-content screening. PK/PD data analysis and interpretation. Demonstrated expertise in immunofluorescence confocal imaging, real-time qPCR array, neurotoxicity and cardiotoxicity, cell stress culture model and assay development.

* Proficient in molecular biology and proteomics techniques: PCR, DNA cloning, DNA/RNA transfection, Northern/Southern, RPA, In situ hybridization, real-time RT-PCR, siRNA, Western, EMSA, DNase I footprinting, in vitro transcription, Chromatin-Immunoprecipitation, Co-immunoprecipitation, protein synthesis in vitro and affinity purification, two dimensional-PAGE gel, mass-spec analysis.

* Highly skillful in mammalian tissue culture and various cell based assay development: transient and stable transfection (lipid-based, retrovirus and lentivirus-based), shRNA transfection, lenti-viral shRNA screening, stable cell lines generation, immunocytochemistry, ELISA, cell-based assays for receptor binding and signaling, phosphorylation, cytokine secretion, cell migration, proliferation and apoptosis.

Management and Supervision

* Managed multiple contract research projects and timelines with pharmaceutical and academic partners in Corning Incoporated.

* Led and managed a team of 5 producing quarterly Newsletter for Ethinic Diverse Group of Employees (EDGE) in Corning Inc from Q1,2010 to Q4, 2012.

* Demonstrated ability to supervise technicians and associate scientists.

Communication

* Communication officer for planning and coordinating diversity employee events and programs in Corning, Inc.

* Treasurer for managing $35,000 annual spending for a 200 people organization EDGE in Corning Inc.

* Adapted working with teams with diverse backgrounds.

Computation

* Demonstrated proficiency with Microsoft Office, bioinformatic software Vector NTI, BLAST, Sanger database, PDB, and SwissPro, Graphpad Prism and SigmaPlot.

Skillsets in Training * Familiar with cGMP and GLP, regulatory guidance (IND, NDA, BLA). Basic understanding of QSR.

EDUCATION

09/2003-08/2007 PhD Pharmacology/Neuroscience, Dalhousie University, Canada

09/1999-03/2002 MSc Biochemistry and Molecular Biology, Dalhousie University, Canada

09/1993-07/1997 BSc Bioloy, HuaZhong Normal University, P.R.China

ACHIEVEMENTS AND AWARDS

2010, 2011, 2012 Annual EDGE diversity best contribution award, Corning Incorporated

2008-2009 Post-doctoral Training Grant ($46,000/year), National Center for Drug Discovery for

Neurodegeneration training grant, Harvard NeuroDiscovery Center (Post-doc)

2005-2007 External Ph.D. scholarship ($21,000/year), Nova Scotia Health Research Foundation (Ph.D.)

2003-2005 External Ph.D. Scholarship ($21,500/year), Huntington Society of Canada Graduate

LandMark Ph.D. scholarship (Ph.D.)

PATENTS

1. Fang Y, Deng H, Hu H, Sun H, He M, Niu W. Compositions and methods for the treatment of pathological conditions related to GPR35 and/or GPR35-hERG complex. (SP10-204P, patent filed and pending)

2. Deichmann O, Fang Y, Ferrie AM, Henry D, Hu H, Walerack C. Methods to study cardiac biology and assess molecule cardiotoxicity. (ID#23885, patent filed and pending)

PUBLICATIONS

1. Pai S, Verrier F, Sun H, Hu H, Ferrie AM, Eshraghi A, Fang Y. Dynamic mass redistribution assay decodes differentiation of neural progenitor stem cells. J Biomol Screen. 2012 17(9):1180

2. Hu H, Deng H, Fang Y. Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist. PLoS One. 2012 7(4):e34934.

3. Deng H, Hu H*, Fang Y. Multiple tyrosine metabolites are GPR35 agonists. Sci Rep. 2012 2:373.

4. Deng H, Hu J, Hu H, He M, Fang Y. Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists. Bioorg Med Chem Lett. 2012 22(12):4148.

5. Deng H, Hu H*, Fang Y. Tyrphostin analogs are GPR35 agonists. FEBS Lett. 2011 585(12):1957.

6. Deng H, Hu H, He M, Hu J, Niu W, Ferrie AM, Fang Y. Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J Med Chem. 2011 54(20):7385.

7. Gomez GT, Hu H, McCaw EA, Denovan-Wright EM. Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation. Mol Cell Neurosci. 2006 31(4):661.

8. Hu H, McCaw EA, Hebb AL, Gomez GT, Denovan-Wright EM. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci. 2004 20(12):3351.

9. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 2004 271(23-24):4909.

*Equal first-author contribution

Contact this candidate